Inhibition of NF-KB signaling unveils novel strategies to overcome drug resistance in cancers

Drug resistance in cancer remains a major challenge in oncology, impeding the effectiveness of various treatment modalities. The nuclear factor-kappa B (NF-KB) signaling pathway has emerged as a critical player in the development of drug resistance in cancer cells. This comprehensive review explores the intricate relationship between NF-KB and drug resistance in cancer. We delve into the molecular mechanisms through which NF-KB activation contributes to resistance against chemotherapeutic agents, targeted therapies, and immunotherapies. Additionally, we discuss potential strategies to overcome this resistance by targeting NF-KB signaling, such as small molecule inhibitors and combination therapies. Understanding the multifaceted interactions between NFKB and drug resistance is crucial for the development of more effective cancer treatment strategies. By dissecting the complex signaling network of NF-KB, we hope to shed light on novel therapeutic approaches that can enhance treatment outcomes, ultimately improving the prognosis for cancer patients. This review aims to provide a comprehensive overview of the current state of knowledge on NF-KB and its role in drug resistance, offering insights that may guide future research and therapeutic interventions in the fight against cancer.